Identification of Blood Serum Micro-RNAs Associated With Idiopathic and LRRK2 Parkinson's Disease

被引:126
|
作者
Botta-Orfila, Teresa [1 ]
Morato, Xavier [1 ]
Compta, Yaroslau [1 ,2 ]
Jose Lozano, Juan [3 ]
Falgas, Neus [2 ]
Valldeoriola, Francesc [1 ,2 ]
Pont-Sunyer, Claustre [1 ,2 ]
Vilas, Dolores [1 ,2 ]
Mengual, Lourdes [4 ]
Fernandez, Manel [1 ]
Luis Molinuevo, Jose [2 ,5 ]
Antonell, Anna [2 ,5 ]
Jose Marti, Maria [1 ,2 ]
Fernandez-Santiago, Ruben [1 ]
Ezquerra, Mario [1 ]
机构
[1] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Invest Enfermedades Neurodegenerat CIBERNED, Lab Neurodegenerat Disorders,Dept Neurol, E-08036 Barcelona, Catalonia, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Movement Disorders Unit,Dept Neurol, Barcelona, Catalonia, Spain
[3] CEK, CIBEREHD, Barcelona, Catalonia, Spain
[4] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Lab & Dept Urol, E-08036 Barcelona, Catalonia, Spain
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Alzheimers Dis & Other Cognit Disorders Unit, Neurol Serv, E-08036 Barcelona, Catalonia, Spain
关键词
Parkinson's disease; biomarker; blood; miRNAs; CIRCULATING MICRORNA; EXPRESSION ANALYSIS; CLINICAL-DIAGNOSIS; ALZHEIMERS-DISEASE; PROTEIN; BIOMARKERS; SIGNATURES; MUTATIONS; NEURONS; CANCER;
D O I
10.1002/jnr.23377
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Blood-cell-free circulating micro-RNAs (miRNAs) have been proposed as potential accessible biomarkers for neurodegenerative diseases such as Parkinson's disease (PD). Here we analyzed the serum levels of 377 miRNAs in a discovery set of 10 idiopathic Parkinson's disease (IPD) patients, 10 PD patients carriers of the LRRK2 G2019S mutation (LRRK2 PD), and 10 controls by using real-time quantitative PCR-based TaqMan MicroRNA arrays. We detected candidate differentially expressed miRNAs, which were further tested in a first validation set consisting of 20 IPD, 20 LRRK2 PD, and 20 control samples. We found four statistically significant miRNAs that were downregulated in either LRRK2 or IPD (miR-29a, miR-29c, miR-19a, and miR-19b). Subsequently, we validated these findings in a third set of samples consisting of 65 IPD and 65 controls and confirmed the association of downregulated levels of miR-29c, miR-29a, and miR-19b in IPD. Differentially expressed miRNAs are predicted to target genes belonging to pathways related to ECM-receptor interaction, focal adhesion, MAPK, Wnt, mTOR, adipocytokine, and neuron projection. Results from our exploratory study indicate that downregulated levels of specific circulating serum miRNAs are associated with PD and suggest their potential use as noninvasive biomarkers for PD. Future studies should further confirm the association of these miRNAs with PD. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1071 / 1077
页数:7
相关论文
共 50 条
  • [21] LRRK2 and membrane trafficking: nexus of Parkinson's disease
    Hur, Eun-Mi
    Jang, Eun-Hae
    Jeong, Ga Ram
    Lee, Byoung Dae
    BMB REPORTS, 2019, 52 (09) : 533 - 539
  • [22] LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease
    Xiong, Yulan
    Dawson, Valina L.
    Dawson, Ted M.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1074 - 1079
  • [23] LRRK2 phosphorylation of Rab GTPases in Parkinson's disease
    Pfeffer, Suzanne R.
    FEBS LETTERS, 2023, 597 (06) : 811 - 818
  • [24] LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease
    Usenko, T. S.
    Senkevich, K. A.
    Basharova, K. S.
    Bezrukova, A. I.
    Baydakova, G. V.
    Tyurin, A. A.
    Beletskaya, M. V.
    Kulabukhova, D. G.
    Grunina, M. N.
    Emelyanov, A. K.
    Miliukhina, I. V.
    Timofeeva, A. A.
    Zakharova, E. Y.
    Pchelina, S. N.
    GENE, 2023, 882
  • [25] LRRK2 contributes to monocyte dysregulation in Parkinson's disease
    Bliederhaeuser, Corinna
    Zondler, Lisa
    Grozdanov, Veselin
    Ruf, Wolfgang P.
    Brenner, David
    Melrose, Heather L.
    Bauer, Peter
    Ludolph, Albert C.
    Gillardon, Frank
    Kassubek, Jan
    Weishaupt, Jochen H.
    Danzer, Karin M.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2016, 4
  • [26] LRRK2 G2019S Mutations are Associated with an Increased Cancer Risk in Parkinson Disease
    Saunders-Pullman, Rachel
    Barrett, Matthew J.
    Stanley, Kaili M.
    San Luciano, Marta
    Shanker, Vicki
    Severt, Lawrence
    Hunt, Ann
    Raymond, Deborah
    Ozelius, Laurie J.
    Bressman, Susan B.
    MOVEMENT DISORDERS, 2010, 25 (15) : 2536 - 2541
  • [27] Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson’s Disease Progression
    Selma Yılmazer
    Esin Candaş
    Gençer Genç
    Merve Alaylıoğlu
    Büşra Şengül
    Ayşegül Gündüz
    Hülya Apaydın
    Güneş Kızıltan
    Sibel Ertan
    Erdinç Dursun
    Duygu Gezen-Ak
    NeuroMolecular Medicine, 2021, 23 : 292 - 304
  • [28] Protein synthesis is suppressed in sporadic and familial Parkinson's disease by LRRK2
    Deshpande, Prasannakumar
    Flinkman, Dani
    Hong, Ye
    Goltseva, Elena
    Siino, Valentina
    Sun, Lihua
    Peltonen, Sirkku
    Elo, Laura L.
    Kaasinen, Valtteri
    James, Peter
    Coffey, Eleanor T.
    FASEB JOURNAL, 2020, 34 (11) : 14217 - 14233
  • [29] Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
    Bright, Jessica M.
    Carlisle, Holly J.
    Toda, Alyssa M. A.
    Murphy, Molly
    Molitor, Tyler P.
    Wren, Paul
    Andruska, Kristin M.
    Liu, Enchi
    Barlow, Carrolee
    MOVEMENT DISORDERS, 2021, 36 (06) : 1362 - 1371
  • [30] LRRK2 G2019S Parkinson's disease with more benign phenotype than idiopathic
    Ben Romdhan, Sawssan
    Farhat, Nouha
    Nasri, Amina
    Lesage, Suzanne
    Hdiji, Olfa
    Ben Djebara, Mouna
    Landoulsi, Zied
    Stevanin, Giovanni
    Brice, Alexis
    Damak, Mariem
    Gouider, Riadh
    Mhiri, Chokri
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 138 (05): : 425 - 431